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The receptor for hyaluronic acid mediated motility 
(RHAMM/CD168) is a leukemia associated antigen eliciting both 
humoral and cellular immune responses in patients with acute 
myeloid leukemia (AML)
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To improve the clinical outcome of AML patients,
immune therapies targeting leukemia associated antigens
(LAAs) might be an approach additionally to chemother-
apy and transplantation of hematopoietic stem cells. Ideal
LAAs should be preferentially expressed in leukemic
blasts, but neither on stem cells of normal hematopoiesis.
RHAMM/CD168 was defined as a LAA using the approach
of serological screening of expression libraries (SEREX),
eliciting IgG responses in 42% of patients with AML, but
not in healthy volunteers (HV) or patients with autoim-
mune diseases. mRNA for RHAMM was demonstrated by
qRT-PCR to be expressed in leukemic blasts of more than
80% of the AML patients, but not in PBMN or CD34+
stem cells of healthy volunteers. Among normal tissues,
only testis, placenta and thymus showed significant
mRNA expression for the antigen, therefore sharing the
expression profile of some other SEREX antigens.
Immunostaining of cytospins and western blots of naive
AML blasts and AML cell lines (e.g. K562) confirmed the
RHAMM expression on the protein level in 70% of the
patients.
To define T cell epitopes of RHAMM, 10 peptides were
synthesized following the SYFPEITHY and PAProC algo-
rithms and subjected to ELISPOT assays for interferon
gamma and granzyme B. CD8+ T cells taken from the
peripheral blood of AML patients and presensitized with
peptide R3 or R5 were specifically reactive in the assays
against T2 cells pulsed with R3/R5 or COS7 cells co-trans-
fected with HLA-A*0201 and RHAMM. The successful co-
transfection was confirmed by flow cytometry and immu-
nocytology. Cross-reactivity was excluded. These results
were confirmed using a Cr-51 release assay.
In an AML patient having received blast-derived dendritic
cells, a higher frequency of RHAMM-directed T cells was
observed after four vaccinations when compared to the
status before vaccination. We are going to initiate a phase-
I vaccination trial using peptide R3 on a carrier molecule
as specific AML vaccine. There is evidence that RHAMM is
also expressed in other leukemia types (CML, CLL) which
might encourage futher clinical trials.
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